Therapeutic monoclonal antibody targeting CCR8 on tumor-infiltrating regulatory T cells, engineered for enhanced ADCC to selectively deplete CCR8+ Tregs and reduce intratumoral immunosuppression.
HC006 is a monoclonal antibody that binds CCR8 on tumor-infiltrating regulatory T cells and is Fc-engineered for enhanced ADCC, recruiting FcγR-expressing effector cells (e.g., NK cells) to selectively deplete CCR8+ Tregs in the tumor microenvironment, thereby reducing intratumoral immunosuppression and promoting antitumor immunity.
NO
INDIRECT
HC006 binds CCR8 on Tregs and uses its Fc to engage CD16a on NK cells to trigger ADCC, killing CCR8+ Tregs; CD16a+ effector cells are not the targets and are not killed.
An intravenous CD19-directed antibody–drug conjugate (ADC), also known as MT-2111. A humanized anti-CD19 monoclonal IgG that binds CD19 on malignant B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) dimer payload (tesirine) via a cleavable linker to create DNA crosslinks and induce apoptosis.
Humanized anti-CD19 monoclonal antibody binds CD19 on B cells, is internalized, and via a cleavable linker releases a pyrrolobenzodiazepine (PBD) dimer payload (tesirine) that forms DNA minor-groove interstrand crosslinks (N2-guanine), blocking DNA replication and inducing apoptosis in CD19-expressing tumor cells.
YES
DIRECT
Anti-CD19 ADC binds CD19, is internalized, and releases a PBD dimer (tesirine) via a cleavable linker that forms DNA interstrand crosslinks, blocking replication and inducing apoptosis in CD19+ cells.
An intravenous CD19-directed antibody–drug conjugate (ADC), also known as MT-2111. A humanized anti-CD19 monoclonal IgG that binds CD19 on malignant B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) dimer payload (tesirine) via a cleavable linker to create DNA crosslinks and induce apoptosis.
Humanized anti-CD19 monoclonal antibody binds CD19 on B cells, is internalized, and via a cleavable linker releases a pyrrolobenzodiazepine (PBD) dimer payload (tesirine) that forms DNA minor-groove interstrand crosslinks (N2-guanine), blocking DNA replication and inducing apoptosis in CD19-expressing tumor cells.
NO
INDIRECT
The ADC binds CD19 on B cells, is internalized, and releases a PBD dimer that crosslinks DNA at N2-guanine in the minor groove, blocking replication and inducing apoptosis. DNA minor-groove binding is the payload’s intracellular action, not the recognition target; killing depends on CD19 expression.
Fully human IgG1 monoclonal antibody immunotherapy that selectively binds CD20 on B lymphocytes and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, while sparing stem cells and plasma cells; suppresses B cell–mediated antigen presentation, T-cell costimulation, cytokine production, and autoantibody-driven inflammation relevant to MS.
Fully human IgG1 monoclonal antibody targeting CD20 on B lymphocytes; induces B-cell depletion via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, sparing stem cells and plasma cells, thereby reducing antigen presentation, T-cell costimulation, cytokine release, and autoantibody-driven inflammation.
YES
DIRECT
Ofatumumab binds CD20 on B cells and induces complement-dependent lysis and Fc-mediated ADCC (with apoptosis), directly depleting CD20+ cells.
Type II, glycoengineered anti-CD20 monoclonal antibody that depletes CD20+ B cells via enhanced ADCC and direct cell death; used as pre-treatment to mitigate CRS.
Glycoengineered, humanized type II anti‑CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases FcγRIIIa binding to enhance ADCC (and ADCP) and induces direct, caspase‑independent cell death, leading to depletion of CD20+ B cells.
YES
DIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages Fc-gammaRIIIa on effector cells to trigger potent ADCC and ADCP, and it also induces direct, caspase-independent cell death of CD20+ cells.